Q4 2019 Bergenbio ASA Earnings Call Transcript
Good morning, my name is Richard Godfrey. I'd like to welcome you to the BerGenBio Q4 presentation and also yearend for 2019. I'm also accompanied here with Rune Skeie as CFO, as you know, we're a publicly traded company. So as to draw your attention to this disclaimer and safe harbor notice and maybe I'll just start off with just an introduction to BerGenBio for those that are not very familiar with us.
We're a biotech company focused in oncology, developing drugs against cancer when it becomes aggressive, cancer is cancer that no longer respond to drugs that's invisible to your immune system and spreads around your body. That's the really dangerous cancer that we need to treat, BerGenBio and our collaborators have identified a key driver of aggressive cancers, it's called AXL, and we today remain the world leaders in understanding AXL biology.
At this moment, we have three anti-AXL drugs in clinical development. Our lead drug is an oral once-a-day anti-AXL pill, and that's in multiple Phase II studies. We're also developing an anti-AXL antibody in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
